$NKTR
Nektar Therapeutics Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000090670923000004 Filed on February 28, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$21.59M	$22.02M	$92.06M
YoY Change	-13.0%	-11.94%	-9.67%
Cost Of Revenue	$7.060M	$6.233M	$21.64M
YoY Change	32.83%	1.14%	-13.1%
Gross Profit	$14.53M	$15.79M	$70.42M
YoY Change	-25.49%	-16.22%	-8.56%
Gross Profit Margin	67.31%	71.7%	76.5%
Selling, General & Admin	$21.08M	$21.94M	$92.33M
YoY Change	-22.89%	-31.74%	-24.84%
% of Gross Profit	145.05%	138.94%	131.12%
Research & Development	$30.47M	$34.74M	$218.3M
YoY Change	-71.59%	-65.13%	-45.46%
% of Gross Profit	209.64%	220.01%	310.03%
Depreciation & Amortization	$2.302M	$3.182M	$12.20M
YoY Change	-38.28%	-7.39%	-6.15%
% of Gross Profit	15.84%	20.15%	17.32%
Operating Expenses	$30.47M	$56.68M	$218.3M
YoY Change	-71.59%	-43.1%	-45.46%
Operating Profit	-$134.7M	-$40.89M	-$376.2M
YoY Change	15.57%	-63.79%	-15.68%
Interest Expense	-$2.371M	-$4.075M	$0.00
YoY Change	-109.02%	-51.07%
% of Operating Profit
Other Income/Expense, Net	-$2.371M		$11.18M
YoY Change	-109.02%		-114.49%
Pretax Income	-$137.1M	-$56.54M	-$365.0M
YoY Change	51.86%	-61.18%	-30.25%
Income Tax	-$63.00K	$3.144M	$3.215M
% Of Pretax Income
Net Earnings	-$137.0M	-$59.69M	-$368.2M
YoY Change	51.58%	-59.02%	-29.71%
Net Earnings / Revenue	-634.52%	-271.03%	-399.98%
Basic Earnings Per Share	-$0.73		-$1.97
Diluted Earnings Per Share	-$0.73	-$0.32	-$1.97
COMMON SHARES
Basic Shares Outstanding	189.2M shares	188.0M shares	187.1M shares
Diluted Shares Outstanding	188.9M shares		187.1M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$456.8M	$505.0M	$505.0M
YoY Change	-31.51%	-31.2%	-31.2%
Cash & Equivalents	$76.96M	$88.23M	$88.23M
Short-Term Investments	$379.9M	$416.8M	$416.8M
Other Short-Term Assets	$11.01M	$15.81M	$15.81M
YoY Change	-47.15%	-32.25%	-32.25%
Inventory	$20.24M	$19.20M	$19.20M
Prepaid Expenses
Receivables	$2.995M	$5.981M	$5.981M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$491.1M	$546.0M	$546.0M
YoY Change	-33.05%	-31.37%	-31.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$27.08M	$32.45M	$85.89M
YoY Change	-55.59%	-46.37%	-51.62%
Goodwill	$0.00	$76.50M
YoY Change	-100.0%	0.0%
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$1.406M	$2.245M	$2.245M
YoY Change	-7.56%	-18.19%	-18.19%
Total Long-Term Assets	$70.68M	$164.6M	$164.6M
YoY Change	-75.68%	-48.81%	-48.81%
TOTAL ASSETS
Total Short-Term Assets	$491.1M	$546.0M	$546.0M
Total Long-Term Assets	$70.68M	$164.6M	$164.6M
Total Assets	$561.7M	$710.6M	$710.6M
YoY Change	-45.15%	-36.39%	-36.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.696M	$12.98M	$12.98M
YoY Change	-70.71%	33.17%	33.17%
Accrued Expenses	$37.41M	$55.22M	$55.22M
YoY Change	-59.63%	-26.81%	-26.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$59.88M	$68.20M	$68.20M
YoY Change	-43.12%	-19.95%	-19.95%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.479M	$7.551M	$275.8M
YoY Change	139.61%	110.22%	-21.77%
Total Long-Term Liabilities	$6.479M	$7.551M	$275.8M
YoY Change	139.61%	110.22%	-21.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$59.88M	$68.20M	$68.20M
Total Long-Term Liabilities	$6.479M	$7.551M	$275.8M
Total Liabilities	$320.9M	$344.0M	$344.0M
YoY Change	-22.91%	-21.41%	-21.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.338B	-$3.201B
YoY Change	14.19%	13.0%
Common Stock	$3.585B	$3.575B
YoY Change	1.33%	1.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$240.9M	$366.6M	$366.6M
YoY Change
Total Liabilities & Shareholders Equity	$561.7M	$710.6M	$710.6M
YoY Change	-45.15%	-36.39%	-36.39%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$137.0M	-$59.69M	-$368.2M
YoY Change	51.58%	-59.02%	-29.71%
Depreciation, Depletion And Amortization	$2.302M	$3.182M	$12.20M
YoY Change	-38.28%	-7.39%	-6.15%
Cash From Operating Activities	-$51.92M	-$57.70M	-$304.0M
YoY Change	-41.29%	-61.92%	-26.33%
INVESTING ACTIVITIES
Capital Expenditures	$433.0K	$512.0K	$5.676M
YoY Change	-89.7%	-108.68%	-62.13%
Acquisitions
YoY Change
Other Investing Activities	$41.03M	$40.53M	$371.5M
YoY Change	-69.49%	-67.86%	70.6%
Cash From Investing Activities	$40.60M	$40.01M	$365.8M
YoY Change	-68.84%	-66.71%	80.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	103.0K	$1.508M
YoY Change	-100.0%	-95.96%	-95.84%
NET CHANGE
Cash From Operating Activities	-$51.92M	-57.70M	-$304.0M
Cash From Investing Activities	$40.60M	40.01M	$365.8M
Cash From Financing Activities	$0.00	103.0K	$1.508M
Net Change In Cash	-$11.27M	-17.59M	$63.01M
YoY Change	-126.35%	-38.91%	-136.27%
FREE CASH FLOW
Cash From Operating Activities	-$51.92M	-$57.70M	-$304.0M
Capital Expenditures	$433.0K	$512.0K	$5.676M
Free Cash Flow	-$52.35M	-$58.22M	-$309.7M
YoY Change	-43.49%	-60.03%	-27.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Local Phone Number LocalPhoneNumber	482-5300
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	0-24006
CY2022	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3134940
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Mission Bay Boulevard South
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
CY2022	dei	City Area Code CityAreaCode	415
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2022	dei	Trading Symbol TradingSymbol	NKTR
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	704000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	189235139	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	San Mateo, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88227000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25218000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	416750000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	708737000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5981000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22492000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	19202000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	15801000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	15808000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	23333000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	545968000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	795581000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	64828000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32451000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60510000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	53435000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117025000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	76501000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	76501000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2245000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2744000	usd
CY2022Q4	us-gaap	Assets Assets	710600000	usd
CY2021Q4	us-gaap	Assets Assets	1117189000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12980000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9747000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9582000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15735000	usd
CY2022Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	12262000	usd
CY2021Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	26809000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14713000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15468000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	18667000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	17441000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	68204000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85200000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	112829000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	125736000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	27726000	usd
CY2022Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	155378000	usd
CY2021Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	195427000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7551000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3592000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	343962000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	437681000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	188560000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	188560000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185468000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	185468000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	19000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	19000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3574719000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3516641000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6907000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4157000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3201193000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2832995000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	366638000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	679508000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	710600000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1117189000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92055000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	101907000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	152915000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21635000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24897000	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19477000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	218323000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	400269000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	408678000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	92333000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	122844000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	104682000	usd
CY2022	nktr	Impairment Of Assets And Other Costs For Terminated Program ImpairmentOfAssetsAndOtherCostsForTerminatedProgram	135930000	usd
CY2021	nktr	Impairment Of Assets And Other Costs For Terminated Program ImpairmentOfAssetsAndOtherCostsForTerminatedProgram	0	usd
CY2020	nktr	Impairment Of Assets And Other Costs For Terminated Program ImpairmentOfAssetsAndOtherCostsForTerminatedProgram	45189000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	468221000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	548010000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	578026000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-376166000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-446103000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-425111000	usd
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	33427000	usd
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-8023000	usd
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	usd
CY2022	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	28911000	usd
CY2021	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	47313000	usd
CY2020	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	30267000	usd
CY2022	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0	usd
CY2021	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	-24410000	usd
CY2020	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6667000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2569000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18282000	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2021	us-gaap	Interest Expense InterestExpense	0	usd
CY2020	us-gaap	Interest Expense InterestExpense	6851000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11183000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77177000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18836000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-364983000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-523280000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-443947000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3215000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	557000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	493000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-368198000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523837000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-444440000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.97
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.97
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.86
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.86
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.49
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.49
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	187138000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	187138000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	183298000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	183298000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	178581000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	178581000	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-368198000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-523837000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-444440000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1114000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1568000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-927000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1636000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-294000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-363000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2750000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1862000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1290000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-370948000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-525699000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-445730000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1405391000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23373000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94261000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-445730000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	33238000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94674000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-525699000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	679508000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	758000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	57320000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-370948000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	366638000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-368198000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-523837000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-444440000	usd
CY2022	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	69794000	usd
CY2021	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	77746000	usd
CY2020	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	48563000	usd
CY2022	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	28911000	usd
CY2021	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	47313000	usd
CY2020	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	30267000	usd
CY2022	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0	usd
CY2021	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	-24410000	usd
CY2020	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sales Of Future Royalties GainLossOnRevaluationOfLiabilitiesRelatedToTheSalesOfFutureRoyalties	0	usd
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	33427000	usd
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-8023000	usd
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4951000	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	16703000	usd
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	57320000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94674000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94261000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13030000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14146000	usd
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14182000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2708000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-102000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-36000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	65761000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3326000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	0	usd
CY2021	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	0	usd
CY2020	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	20351000	usd
CY2022	nktr	Amortization Of Premiums Discounts Net And Other Non Cash Transactions AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions	2435000	usd
CY2021	nktr	Amortization Of Premiums Discounts Net And Other Non Cash Transactions AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions	-6730000	usd
CY2020	nktr	Amortization Of Premiums Discounts Net And Other Non Cash Transactions AmortizationOfPremiumsDiscountsNetAndOtherNonCashTransactions	-3943000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-16511000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12397000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1913000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3401000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	509000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2627000	usd
CY2022	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	2680000	usd
CY2021	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-2340000	usd
CY2020	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-2743000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-6906000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2586000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4512000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3103000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11690000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2382000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-6153000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1203000	usd
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4697000	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-12734000	usd
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-23524000	usd
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	8644000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1060000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-605000	usd
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5516000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-304007000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-412660000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-313287000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	467914000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	960689000	usd
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	987533000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	826229000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1166951000	usd
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1449304000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	11504000	usd
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	41700000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5676000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14989000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7258000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	13196000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	365835000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	202777000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	496213000	usd
CY2020	nktr	Sale Of Future Royalties Transaction Costs SaleOfFutureRoyaltiesTransactionCosts	3800000	usd
CY2022	nktr	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	0	usd
CY2021	nktr	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	0	usd
CY2020	nktr	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	146250000	usd
CY2022	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	usd
CY2021	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	usd
CY2020	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	250000000	usd
CY2022	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	750000	usd
CY2021	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	3000000	usd
CY2020	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	758000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	33238000	usd
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	23396000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1508000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	36238000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-80354000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-327000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-92000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	63009000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-173737000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	102592000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25218000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198955000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96363000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88227000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25218000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198955000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	9742000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	272000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	325000	usd
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	539000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1057000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2133000	usd
CY2022	nktr	Noncash Investing And Financing Activities Accounts Receivable Recognized In Exchange For Long Term Liabilities NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities	0	usd
CY2021	nktr	Noncash Investing And Financing Activities Accounts Receivable Recognized In Exchange For Long Term Liabilities NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities	0	usd
CY2020	nktr	Noncash Investing And Financing Activities Accounts Receivable Recognized In Exchange For Long Term Liabilities NoncashInvestingAndFinancingActivitiesAccountsReceivableRecognizedInExchangeForLongTermLiabilities	4000000	usd
CY2022Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	505000000	usd
CY2021	nktr	Net Expense Reimbursements From Collaboration Partner NetExpenseReimbursementsFromCollaborationPartner	21400000	usd
CY2022	nktr	Number Of Reporting Units To Evaluate Goodwill For Impairment NumberOfReportingUnitsToEvaluateGoodwillForImpairment	1	reporting_unit
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1400000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88227000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25218000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	416750000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	708737000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	64828000	usd
CY2022Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	504977000	usd
CY2021Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	798783000	usd
CY2022Q4	nktr	Investmnets Target Maturity Period InvestmnetsTargetMaturityPeriod	P2Y
CY2022	nktr	Investments Weighted Average Maturity Period InvestmentsWeightedAverageMaturityPeriod	P1Y
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	11500000	usd
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	41700000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	700000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	429502000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	25000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1801000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	427726000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	762625000	usd
CY2022Q4	us-gaap	Cash Cash	8798000	usd
CY2021Q4	us-gaap	Cash Cash	1250000	usd
CY2022Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	504977000	usd
CY2021Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	798783000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	700000	usd
CY2022Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	7500000	usd
CY2021Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	8100000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2575000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3166000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	10749000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9342000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5878000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3293000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	19202000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	15801000	usd
CY2022Q4	nktr	Depreciable Property Plant And Equipment Gross DepreciablePropertyPlantAndEquipmentGross	154652000	usd
CY2021Q4	nktr	Depreciable Property Plant And Equipment Gross DepreciablePropertyPlantAndEquipmentGross	201386000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	124731000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	148039000	usd
CY2022Q4	nktr	Depreciable Property Plant And Equipment Net DepreciablePropertyPlantAndEquipmentNet	29921000	usd
CY2021Q4	nktr	Depreciable Property Plant And Equipment Net DepreciablePropertyPlantAndEquipmentNet	53347000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2530000	usd
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	7163000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32451000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60510000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12200000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13000000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12500000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	17057000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	19153000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	18985000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	10700000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	8974000	usd
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	8179000	usd
CY2022	us-gaap	Lease Cost LeaseCost	27757000	usd
CY2021	us-gaap	Lease Cost LeaseCost	28127000	usd
CY2020	us-gaap	Lease Cost LeaseCost	27164000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	20100000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	16800000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	16200000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19216000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	21572000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	22254000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	22958000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	23681000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	51732000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	161413000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	29917000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	131496000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	18667000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	112829000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2022	nktr	Subleases Income To Be Received SubleasesIncomeToBeReceived	10500000	usd
CY2021Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	198344000	usd
CY2012Q1	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	0	usd
CY2022	nktr	Royalty Monetization Proceeds RoyaltyMonetizationProceeds	0	usd
	nktr	Royalty Monetization Proceeds RoyaltyMonetizationProceeds	274000000	usd
CY2022	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	69794000	usd
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	403245000	usd
CY2022	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	28911000	usd
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	273184000	usd
CY2022	nktr	Partial Repayment Of Royalty Sale Proceeds PartialRepaymentOfRoyaltySaleProceeds	0	usd
	nktr	Partial Repayment Of Royalty Sale Proceeds PartialRepaymentOfRoyaltySaleProceeds	10000000	usd
CY2022	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sale Of Future Royalties Gross GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross	0	usd
	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sale Of Future Royalties Gross GainLossONRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross	-23522000	usd
CY2022Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	157461000	usd
CY2022Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	157461000	usd
CY2022Q4	nktr	Liabilities On Sale Of Future Royalties Unamortized Transaction Costs LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts	2083000	usd
CY2022Q4	nktr	Liabilities On Sale Of Future Royalties Unamortized Transaction Costs LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts	2083000	usd
CY2022Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	155378000	usd
CY2022Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	155378000	usd
CY2018Q2	nktr	Stock Issued During Period Subject To Lock Up And Stand Still Provisions Period StockIssuedDuringPeriodSubjectToLockUpAndStandStillProvisionsPeriod	P5Y
CY2022Q4	nktr	Sale Of Stock Value Authorized In Transaction SaleOfStockValueAuthorizedInTransaction	300000000	usd
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	27403000	shares
CY2022	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	1913000	usd
CY2021	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	436000	usd
CY2020	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	55849000	usd
CY2022	us-gaap	Business Exit Costs1 BusinessExitCosts1	31693000	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	30904000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	65761000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3326000	usd
CY2022	us-gaap	Loss On Contract Termination LossOnContractTermination	10898000	usd
CY2022	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	135930000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	67875000	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	2114000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	65761000	usd
CY2022	nktr	Change In Control Severance Payment Period For Executives ChangeInControlSeverancePaymentPeriodForExecutives	P12M
CY2022	nktr	Change In Control Severance Payment Period For Executives ChangeInControlSeverancePaymentPeriodForExecutives	P12M
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.641
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	57320000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94674000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94261000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	83100000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.029
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.012
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.004
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.779
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.638
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5715000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.18
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.07
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.70
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13542000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.62
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6276000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.76
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	15000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.43
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	20.73
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14088000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.40
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M15D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6029000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	27.82
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y7M6D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	17300000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	15900000	usd
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.60
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	12000	usd
CY2020	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	6000	usd
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	6000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2500000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3600000	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3500000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-371900000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-524440000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-445370000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	6917000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1160000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1423000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-364983000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-523280000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-443947000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-608000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	50000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	165000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1115000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	609000	usd
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	364000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	507000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	659000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	529000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	2708000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-102000	usd
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-36000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2708000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-102000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-36000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3215000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	557000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	493000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-76647000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-109889000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-93229000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	987000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4727000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3081000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	51108000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	97914000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	87060000	usd
CY2022	nktr	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards	12348000	usd
CY2021	nktr	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards	286000	usd
CY2020	nktr	Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Carryforwards EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossCarryforwards	286000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	15778000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	6627000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	7929000	usd
CY2022	nktr	Effective Income Tax Rate Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount	6071000	usd
CY2021	nktr	Effective Income Tax Rate Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount	9936000	usd
CY2020	nktr	Effective Income Tax Rate Reconciliation Non Deductible Expense For Liability Related Sale Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonDeductibleExpenseForLiabilityRelatedSaleOfFutureRoyaltiesAmount	6356000	usd
CY2022	nktr	Effective Income Tax Rate Reconciliation Non Cash Royalty Revenue Related To Sales Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount	-7112000	usd
CY2021	nktr	Effective Income Tax Rate Reconciliation Non Cash Royalty Revenue Related To Sales Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount	-7891000	usd
CY2020	nktr	Effective Income Tax Rate Reconciliation Non Cash Royalty Revenue Related To Sales Of Future Royalties Amount EffectiveIncomeTaxRateReconciliationNonCashRoyaltyRevenueRelatedToSalesOfFutureRoyaltiesAmount	-7967000	usd
CY2022	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	0	usd
CY2021	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	4940000	usd
CY2020	us-gaap	Income Tax Reconciliation Disposition Of Assets IncomeTaxReconciliationDispositionOfAssets	0	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2656000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3361000	usd
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3139000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3215000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	557000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13935000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	493000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	545508000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	564712000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	142198000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	139996000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	38445000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	0	usd
CY2022Q4	nktr	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	28254000	usd
CY2021Q4	nktr	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	34680000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	22110000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	33408000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	24134000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	nktr	Deferred Tax Assets Liability Related To The Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties	13424000	usd
CY2021Q4	nktr	Deferred Tax Assets Liability Related To The Sale Of Future Royalties DeferredTaxAssetsLiabilityRelatedToTheSaleOfFutureRoyalties	23757000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	17290000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	828008000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	813843000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	816235000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	785748000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11773000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	28095000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	11335000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	27204000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	2451000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	392000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	564000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14178000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	27768000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2405000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	327000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30500000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	115600000	usd
CY2022Q4	nktr	Operating Loss Carryforwards Subject To Expiration OperatingLossCarryforwardsSubjectToExpiration	1300000000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	80604000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	78665000	usd
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	77410000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	378000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2371000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2512000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	5272000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	58000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	193000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	490000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1450000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	409000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	85845000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	80604000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	78665000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	usd
CY2022	nktr	Unrecognized Tax Benefits Period Increase Decrease Reasonable Period Of Change UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange	P12M
CY2022	nktr	Number Of Operating Business Segment NumberOfOperatingBusinessSegment	1	segment
CY2022	nktr	Number Of Operating Business Segment NumberOfOperatingBusinessSegment	1	segment
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92055000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	101907000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	152915000	usd

Files In Submission

Name	View Source	Status
nktr-20221231_lab.xml	Edgar Link	unprocessable
0000906709-23-000004-index-headers.html	Edgar Link	pending
0000906709-23-000004-index.html	Edgar Link	pending
0000906709-23-000004.txt	Edgar Link	pending
0000906709-23-000004-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nktr-20221231.htm	Edgar Link	pending
nktr-20221231.xsd	Edgar Link	pending
nktr-20221231xexx311.htm	Edgar Link	pending
nktr-20221231xexx312.htm	Edgar Link	pending
nktr-20221231xexx321.htm	Edgar Link	pending
nktr-20221231_g1.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nktr-20221231_cal.xml	Edgar Link	unprocessable
nktr-20221231_def.xml	Edgar Link	unprocessable
nktr20221231-exx211.htm	Edgar Link	pending
nktr20221231-exx231.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
nktr-20221231_pre.xml	Edgar Link	unprocessable
nktr-20221231_htm.xml	Edgar Link	completed
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
Nektar Therapeutics Stock $nktr

2023 Q1 Form 10-K Financial Statement

#000090670923000004 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR Nektar Therapeutics Stock $nktr

2023 Q1 Form 10-K Financial Statement

#000090670923000004 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
Nektar Therapeutics Stock $nktr